To further investigate whether HSF1 inhibition could inhibit the progression of pancreatic cancer, starting at 8 weeks of age, when KPC mice have developed widespread advanced pancreatic neoplasia, we treated the KPC mice daily with vehicle or KRIBB11 (N(2)‐(1H‐indazole‐5‐yl)‐N(6)‐methyl‐3‐nitropyridine‐2,6‐diamine) (50 mg·kg−1), which is a potent HSF1 inhibitor (Yoon et al., 2011). This evidence concerns the gene HSF1 and familial pancreatic carcinoma.